Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort

Scandinavian Journal of Infectious Diseases

Volumn 44, Issue 1, 2012, Pages 37-43

  Allavena, Clotilde ^a   Flandre, Philippe ^b   Pugliese, Pascal ^c   Valantin, Marc Antoine ^d   Poizot Martin, Isabelle ^e   Cabié, André ^b   Melliez, Hugues ^f   Cuzin, Lise ^g   Duvivier, Claudine ^h,i   Dellamonica, Pierre ^c   Raffi, François ^a  

^a HÔTEL DIEU   (France)

^b INSERM   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔPITAL SAINTE MARGUERITE   (France)

^f CENTRE HOSPITALIER DE TOURCOING   (France)

^g CHU PURPAN   (France)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

ⁱ INSTITUT PASTEUR   (France)

Author keywords

HIV; Multidrug resistance; Protease inhibitors; Tipranavir

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; AMPRENAVIR; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; CHOLESTEROL; DARUNAVIR; ENFUVIRTIDE; FOSAMPRENAVIR; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MARAVIROC; NELFINAVIR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR; TRIACYLGLYCEROL;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CYTOLYSIS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CYTOLYSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS MUTATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIDINES; PYRONES; RITONAVIR; VIRAL LOAD;

EID: 84555169347     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.598870     Document Type: Article

References (26)

1. Guidelines for the Use of Antiretroviral Agents in HIV- 1-Infected Adults and Adolescents Panel on Antiretroviral Guidelines for Adults and Adolescents Bethesda, MD: US Department of Health and Human Services; December 1, 2009. Available at: HYPERLINK http://www.aidsinfo.nih. gov/ContentFiles/ AdultandAdolescentGL.pdf http://www. aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf (accessed date: 1 October 2010).
2. Hicks CB, Cahn P, Cooper DA, Walmsley SL, Katlama C, Clotet B, et al. Durable effi cacy of tipranavir - ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1- infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466-75. (Pubitemid 44142769)
3. Markowitz M, Slater LN, Schwartz R, Kazanjian PH, Hathaway B, Wheeler D, et al. Long-term effi cacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study. J Acquir Immune Defi c Syndr 2007; 45:401-10. (Pubitemid 47061412)
4. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. POWER 1 and 2 study groups. Effi cacy and safety of darunavir - ritonavir at week 48 in treatmentexperienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomized trials. Lancet 2007;369:1169-78. (Pubitemid 46541620)
5. Talbot A, Grant P, Taylor J, Baril JG, Liu TF, Charest H, et al. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother 2010;54:2473-9.
6. Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, et al. Effi cacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatmentnaive HIV-1-infected patients at week 48. AIDS 2008;22: 1389-97.
7. Mitsuya Y, Liu TF, Rhee SY, Fessel WJ, Shafer RW. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis 2007;196:1177-9. (Pubitemid 47580272)
8. Koh Y, Amano M, Towata T, Danish M, Leshchenko-Yashchuk S, Das D, et al. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors. J Virol 2010;84:11961-9.
9. Temesgen Z, Feinberg J. Tipranavir: a new option for the treatment of drug-resistant HIV infection. Clin Infect Dis 2007;45:761-9. (Pubitemid 47381280)
10. Luna B, Townsend MU. Tipranavir: the fi rst nonpeptidic protease inhibitor for the treatment of protease resistance. Clin Ther 2007;29:2309-18. (Pubitemid 350298126)
11. Pierone G Jr, Urban T, Martin A, Mieras J, Kantor C. Successful use of a tipranavir/ritonavir-based antiretroviral regimen following development of viral resistance to darunavir. HIV Clin Trials 2008;9:140-1. (Pubitemid 351816802)
12. Cahn P, Villacian J, Lazzarin A, Katlama C, Grinsztejn B, Arasteh K, et al. Ritonavir-boosted tipranavir demonstrates superior effi cacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006;43:1347-56. (Pubitemid 44706465)
13. Gathe J, Cooper DA, Farthing C, Jayaweera D, Norris D, Pierone G Jr, et al. Effi cacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006;43: 1337-46. (Pubitemid 44706464)
14. Pugliese P, Cuzin L, Cabié A, Poizot-Martin I, Allavena C, Duvivier C, et al. A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med 2009;10: 504-11.
15. Marcelin AG, Masquelier B, Descamps D, Izopet J, Charpentier C, Alloui C, et al. Tipranavir - ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2008;52:3237-43.
16. Baxter JD, Schapiro JM, Boucher CA, Kohlbrenner VM, Hall DB, Scherer JR, et al. Genotypic changes in human immunodefi ciency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006;80:10794-801. (Pubitemid 44628925)
17. Johnson VA, Brun-Vé zinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18:156-63.
18. Schapiro JM, Scherer J, Boucher CA, Baxter JD, Tilke C, Perno CF, et al. Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score. Antivir Ther 2010; 15:1011-9.
19. Bethell R, Hall DB, Baxter J, Schapiro J, Boucher C, Scherer J. No effect of subtype on susceptibility and virological response to TPV/r for treatment experienced patients. Abstract A121. 17 th International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Sitges, Spain, 10 - 14 June 2008. Antivir Ther 2008;13(Suppl 3):A121.
20. Hsieh SM, Chang SY, Hung CC, Sheng WH, Chen MY, Chang SC. Impact of fi rst-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure. BMC Infect Dis 2009;9:154.
21. Baxter JD, Bhatti L, Coakley E, Bartczak J, McDonough M, Vinisko R, et al. Susceptibility of HIV-1 to tipranavir and other antiretroviral agents in treatment-experienced patients: the UTILIZE study. Curr HIV Res 2010;8:347-54.
22. Raffi F, Battegay M, Rusconi S, Opravil M, Blick G, Steigbigel RT, et al. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 2007;21:1977-80. (Pubitemid 47333873)
23. Abel S, van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ, et al. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 2008;65:5-18. (Pubitemid 351366533)
24. Hanley WD, Wenning LA, Moreau A, Kost JT, Mangin E, Shamp T, et al. Effect of tipranavir - ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2009;53:2752-5.
25. Khanlou H, Allavena C, Billaud E, McKellar M, Reliquet V. Development of hepatic cytolysis after switching from enfuvirtide to raltegravir in virologically suppressed patients treated with tipranavir/ritonavir. Abstract TUPE0087. 17 th International AIDS Conference, Mexico City, Mexico, August 2008.
26. Schöl ler M, Kraft M, Hoetelmans R, Vyncke V, Vandermeulen K, Peeters M, et al. Signifi cant decrease in TMC125 exposures when co-administered with tipranavir (boosted with ritonavir) in healthy subjects. Abstract 583. 13 th Conference on Retroviruses and Opportunistic Infections, Denver, CO, USA, February 2006.